Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant

FLT3‐ITD–mutated acute myeloid leukemia (AML) has very high risk of relapse and is associated with poor outcome following allogeneic hematopoietic‐cell transplant (allo‐HCT). This two‐part, phase 1, multicenter, open‐label, sequential‐group, dose‐escalation study aimed to determine dose‐limiting tox...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandmaier, Brenda M., Khaled, Samer, Oran, Betül, Gammon, Guy, Trone, Denise, Frankfurt, Olga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585789/
https://www.ncbi.nlm.nih.gov/pubmed/29090473
http://dx.doi.org/10.1002/ajh.24959

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585789/
https://www.ncbi.nlm.nih.gov/pubmed/29090473
http://dx.doi.org/10.1002/ajh.24959

Ejemplares similares